This latest round of funding was conducted with financial advice from Seaview Securities and advised by Fox Rothschild Technology and Venture Finance Group.
The funds will be used to help Topaz complete clinical trials of the company’s new prescription medicine to fight head lice, and prepare the product for market.
Nick Spring, president and CEO of Topaz Pharmaceuticals, said: “This round of funding is a significant milestone in the evolution of Topaz Pharmaceuticals.”